NeuroAI NEUROAINEUROAI.SITE
China AI, reported clearly
1,300+ verified stories on models, robotics, BCI and the business of AI.
Browse stories
ESC

A Filing, Not an Approval: China Registers Its First Non-Invasive BCI Clinical Study Under New Rules

On November 5, a clinical study combining non-invasive brain control, spinal stimulation and a hybrid exoskeleton for chronic stroke patients completed filing with the National Health Commission — the first non-invasive BCI clinical research project registered since China's biomedical new-technology regulations took effect in May. A filing creates a pathway for research; it is not a marketing approval.

2026-11-18 · 832 words · NeuroAI
A Filing, Not an Approval: China Registers Its First Non-Invasive BCI Clinical Study Under New Rules

A rehabilitation technology project filed paperwork with China's National Health Commission on November 5 — and that bureaucratic act says more about how brain-computer interfaces will be governed in China than any product launch this year.

The study, titled "Safety and Feasibility of SCS Combined with Non-invasive Brain-Controlled Hybrid Exoskeleton Training for Lower-Limb Motor Impairment in Chronic Stroke" (《SCS联合无创脑控混动外骨骼训练治疗慢性卒中下肢运动障碍的安全性与可行性探索研究》), formally completed its biomedical new-technology clinical research filing (临床研究备案) with the National Health Commission. Per Securities Daily reporting carried by the China Economic Net and industry commentary, it is the first non-invasive BCI clinical research project to complete such a filing since the Regulation on Clinical Research and Translational Application of Biomedical New Technologies (《生物医学新技术临床研究和转化应用管理条例》), issued as State Council Order No. 818, took effect in May 2026.

Two clarifications belong up front. First, "filing" (备案) means the study has been registered and cleared to proceed as clinical research under the new framework — it does not mean the technology has been approved as a marketed therapy. Second, although Shanghai's parallel policy moves drew much of the media attention, the study itself is a Tianjin project, developed by the Haihe Laboratory of Brain-Computer Interaction and Human-Machine Integration (脑机交互与人机共融海河实验室) at Tianjin University, with the clinical trial conducted at Tianjin Huanhu Hospital.

What the study actually does

The project's core equipment is the "Shengong-Shenchi" (神工-神驰) system, described by the research team as a composite brain-spine-body neural regulation and rehabilitation platform. Rather than a single brain-controlled exoskeleton, it chains three technologies into one closed loop:

  • A non-invasive brain-computer interface decodes the patient's movement intention from brain signals — no implant required.
  • Spinal cord stimulation (脊髓电刺激) modulates the spinal circuits' excitability between brain and limbs.
  • A hybrid-driven exoskeleton, assisted by functional electrical stimulation of the tibialis anterior muscle, executes the gait movement.

The stated goal is to shift rehabilitation from "the machine dragging the patient through walking" toward active, intention-driven training that may induce the patient's own neural plasticity to rebuild motor pathways. The target population is chronic stroke patients whose lower-limb recovery has plateaued — a large cohort for whom few options remain.

Co-developers listed in the filings include Suishi (Tianjin) Intelligent Technology and Beijing Pings Medical (品驰医疗), an established maker of implanted neuromodulation devices.

Why the filing system matters

The May 2026 regulation created a national registration regime for clinical research on biomedical new technologies, BCI included. Before it, novel neural-interface studies proceeded under hospital-level ethics approval with uneven national visibility. The filing regime puts projects on a national record, standardized in scope and safety review, before any human testing.

The November 5 filing is the signal that researchers are actually using the new pathway — and specifically that non-invasive BCI, which in China's clinical-research pipeline had lagged behind the implant-based race for regulatory firsts, now has a formal route. China's implant-based track moved fast this year: the NEO system became the world's first approved invasive BCI medical device in March, with its first prescription and commercial implantation at Huashan Hospital in July.

Shanghai's parallel move: regulation, not just research

Four days after the filing, Shanghai moved on the governance side. On November 9, the city's food and drug safety committee released its "15th Five-Year" plan (十五五规划) for drug safety and high-quality pharmaceutical industry development. The plan's frontier-technology section commits to strengthening whole-chain service and supervision of BCI medical devices, including:

  • Improving the pre-market regulatory system for BCI devices.
  • Building a dedicated standards system for BCI medical devices.
  • Developing evaluation methods and test tooling for new micro-nano neural electrode functions.
  • Establishing a "research-inspection-review-surveillance" linkage mechanism connecting review, testing and post-market risk monitoring.

Shanghai's plan is a published government planning document — a statement of regulatory direction for the 2026–2030 period, not a binding technical standard itself. The standards it calls for still have to be drafted and issued.

Honest limitations

  • The "first non-invasive BCI filing" characterization comes from Securities Daily reporting and analyst commentary; the NHC's filing database itself was not directly reviewed for this article, so completeness of the national picture cannot be confirmed.
  • The Shengong-Shenchi system's performance claims come from the research team's own descriptions; no peer-reviewed efficacy data for this specific configuration is cited in the available reporting.
  • A completed filing establishes that the study may proceed; it says nothing about results, and the study's safety and feasibility outcomes are not yet known.
  • Shanghai's plan is directional policy; specific BCI device standards, timelines and enforcement mechanisms remain to be published.

What readers can do now

  • Clinicians in rehabilitation medicine can track the study's registration details and eventual results, since stroke rehabilitation is the most probable near-term application area for non-invasive BCI in China.
  • Device developers should read the May 2026 regulation and Shanghai's plan together: the combination of a national filing regime plus city-level standards roadmaps is becoming the de facto compliance template.
  • Patient advocates can use the distinction between filing and approval when evaluating claims — a project being "registered" or "filed" does not mean a therapy is proven or commercially available.

Related coverage

Cite this article

NeuroAI (脑机网), "A Filing, Not an Approval: China Registers Its First Non-Invasive BCI Clinical Study Under New Rules," 18 November 2026, https://neuroai.site/a/na-brain-shanghai-first-noninvasive-filing

Machine-readable: BibTeX · RIS · JSON · Markdown

More in “Brain–Computer Interface” → · Back to home · Markdown version

China AI, reported clearly
1,300+ verified stories on models, robotics, BCI and the business of AI.
Browse stories